Search results for "Desogestrel"

showing 4 items of 4 documents

Binding of oral contraceptive progestogens to serum proteins and cytoplasmic receptor

1990

Abstract Some progestogens widely used in oral contraceptives are characterized at the level of high-affinity receptor binding as well as binding to sex hormone-binding globulin and corticosteroid-binding globulin. With regard to binding to sex hormone-binding globulin, gestodene, levonorgestrel, and to a lesser extent 3-ketodesogestrel (which is only formed from the prodrug desogestrel in the body), show a behavior that is manifested in the relatively high affinity to sex hormone-binding globulin, whereas desogestrel and norgestimate do not display any measurable affinity for this specific steroid-binding serum protein. Furthermore, levonorgestrel and gestodene dissociate very much more sl…

MaleCytoplasmmedicine.medical_specialtyNorpregnenesmedicine.medical_treatmentReceptors Cell SurfaceLevonorgestrelCytoplasmic receptorGestodeneBinding CompetitiveContraceptives Oral HormonalSex hormone-binding globulinPregnancyDesogestrelSex Hormone-Binding GlobulinInternal medicineNorgestrelmedicineAnimalsHumansLevonorgestrelProgesteroneTranscortinDesogestrelProgesterone CongenersProgestogenbiologybusiness.industryNorgestrelUterusObstetrics and GynecologyRats Inbred StrainsBlood ProteinsNorgestimateRatsKineticsEndocrinologybiology.proteinFemaleProgestinsbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugAmerican Journal of Obstetrics and Gynecology
researchProduct

Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproteron…

2017

Abstract Background Although oral contraceptives (OCs) are the most common treatment in women with polycystic ovary syndrome (PCOS), their effects and safety on the metabolic profiles of these patients are relatively unknown. In this meta-analysis the effects of the different durations (from 3 months to 1 year) of OC treatment using cyproterone acetate (CA) or third generation progestins on metabolic profile of patients with PCOS were assessed. Materials and methods PubMed, Scopus, Google Scholar and ScienceDirect databases (2001–2015) were searched to identify clinical trials investigating the effects of OC containing CA or third generation progestins on metabolic profiles of women with PC…

Blood Glucosemedicine.medical_specialtyTime Factorsmedicine.drug_classEndocrinology Diabetes and MetabolismBlood lipidsBlood Pressure030209 endocrinology & metabolism03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInsulin resistanceDesogestrelInternal medicinemedicineHumansInsulinCyproterone AcetateClinical Trials as Topic030219 obstetrics & reproductive medicinebusiness.industryBody WeightCyproterone acetateDrospirenoneLipid Metabolismmedicine.diseasePolycystic ovaryEndocrinologychemistryMetabolomeFemaleProgestinsbusinessProgestinBody mass indexContraceptives OralPolycystic Ovary Syndromemedicine.drugMetabolism
researchProduct

Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?

2013

""The primary aim of the study was to analyze the endometrioma recurrence rate in patients who underwent laparoscopic excision followed by postoperative long-term regimen of oral contraceptives (OCs).. . MATERIALS AND METHODS: 168 patients who underwent a conservative laparoscopic surgery for endometrioma, during the period between September 2009 and August 2010 in three university hospitals were studied. A long-term OCs therapy was offered to all women following surgery. Patients were randomly divided into three groups according to different progestins used (desogestrel, gestodene, dienogest). Women who refused a postoperative hormonal therapy served as control. Follow-up visits and transv…

minimally invasive gynecologic surgeryAdultmedicine.medical_specialtyEndometriosis endometrioma recurrencee oral contraceptives minimally invasive gynecologic surgery progestins dienogest.AdolescentNorpregnenesendometrioma recurrenceeEndometriosisEndometriosisKaplan-Meier EstimateDrug Administration Schedulelaw.inventionYoung Adultchemistry.chemical_compoundRandomized controlled triallawSecondary PreventionHumansNandroloneMedicineIn patientOvarian DiseasesYoung adultLaparoscopyoral contraceptivesDesogestrelmedicine.diagnostic_testbusiness.industryObstetricsObstetrics and GynecologyEndometriosis Endometrioma recurrence Oral contraceptives Minimally invasive gynaecologic surgery Progestins DienogestGeneral MedicineLaparoscopic excisionmedicine.diseaseCombined Modality TherapySurgeryRegimenTreatment OutcomeDienogestchemistryprogestinsdienogestFemaleLaparoscopybusinessContraceptives OralFollow-Up Studies
researchProduct

Protrhombotic Effects of Contraceptives

2010

The use of oral contraceptives first became widespread some 40 years ago, and reports of an excess risk of cardiovascular disease among women who used these agents soon followed. Few drugs have been the object of such intensive epidemiological research, the outcome of which has provided clinicians with detailed information about risks not only of specific thrombotic diseases but also important non-contraceptive benefits from the pill. Recently, oral contraceptives have been classified by some according to "generation" (first, second, third, and most recently, fourth generation): first-generation formulations containing lynestrenol or norethindrone, second-generation formulations containing …

medicine.medical_specialtymedicine.drug_classLipid Metabolism DisordersMyocardial InfarctionPhysiologyGestodeneRisk AssessmentRisk FactorsDesogestrelInternal medicineDrug DiscoverymedicineHumansLevonorgestrelGlucose Metabolism DisordersVenous ThrombosisPharmacologyHemostasisbusiness.industryModels CardiovascularAtherosclerosisLipid MetabolismNorgestimateSettore MED/11 - Malattie Dell'Apparato CardiovascolareLynestrenolEndocrinologyEstrogenPillHypertensionFemaleRisk assessmentbusinessTrhombosis contraceptivesContraceptives Oralmedicine.drugCurrent Pharmaceutical Design
researchProduct